Luspatercept

A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor type IIb (ActRIIb) and linked… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Beta-thalassemia is a hereditary disorder with limited approved treatment options; patients experience anemia and its… (More)
Is this relevant?
2019
2019
Anemia of lower risk MDS and PMF generally becomes resistant to available treatments, leading to RBC transfusions, iron overload… (More)
Is this relevant?
2017
2017
BACKGROUND Myelodysplastic syndromes are characterised by ineffective erythropoiesis. Luspatercept (ACE-536) is a novel fusion… (More)
Is this relevant?
2017
2017
Luspatercept (ACE-536, ACVR2B-Fc), a fusion protein consisting of the extracellular domain of ActRIIB receptor and the Fc-part of… (More)
  • table 2
  • table 3
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2017
Review
2017
INTRODUCTION Regular transfusion and iron chelation are the current treatment of severe forms of thalassemia. As a consequence of… (More)
Is this relevant?
Review
2017
Review
2017
Patients with lower-risk myelodysplastic syndromes (MDS) are mainly affected by chronic anemia and fatigue. Treatment strategies… (More)
Is this relevant?
2016
2016
• In b-thalassemia, imbalances in the production of a and b globin chains inhibit late-stage erythroid differentiation, leading… (More)
  • figure 2
Is this relevant?
2016
2016
Luspatercept Increases Hemoglobin, Reduces Liver Iron Concentration and Improves Quality of Life in Non-Transfusion Dependent… (More)
  • figure 1
Is this relevant?